<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253383</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000452966</org_study_id>
    <secondary_id>R01CA101704</secondary_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-0226</secondary_id>
    <secondary_id>DMS-CPHS-16004</secondary_id>
    <nct_id>NCT00253383</nct_id>
  </id_info>
  <brief_title>Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients</brief_title>
  <official_title>Improving Palliative Care for Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Palliative care may help patients with advanced cancer live more comfortably.

      PURPOSE: This randomized clinical trial is studying an early intervention palliative care
      program to see how well it works compared to a standard care program in improving end-of-life
      care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of an early intervention palliative care program comprising a
           phone-based nurse educator and shared medical appointments in improving end-of-life care
           of patients with advanced lung, gastrointestinal, genitourinary, or breast cancer.

        -  Compare symptom management, quality of life, and the match between preference of care
           and the care received in patients treated with an early intervention palliative care
           program vs a standard care program.

        -  Compare health care utilization by patients treated with these interventions.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to cancer
      diagnosis (lung vs breast vs gastrointestinal vs genitourinary) and participating center.
      Patients are randomized to 1 of 2 intervention arms.

        -  Arm I (early-intervention palliative care program): Patients complete the Medical Care
           Questionnaire and receive a computer-generated prescription letter that outlines the
           problems they have identified; the patient's physician also receives a copy of the
           letter. Patients receive a series of phone calls weekly for 4 weeks and then at least
           monthly from a nurse educator. The phone calls address 3 major areas: coordination of
           palliative care options in the cancer center and the patient's community, including
           referrals for psychological or spiritual counseling, social work consultation, financial
           guidance, home health, palliative care or hospice services, and bereavement counseling
           for the family; problem-solving therapy, focusing on the identification of problems,
           definition of achievable goals, a plan for reaching those goals, and evaluation of
           success; and tailored psycho-educational modules from &quot;Charting Your Course&quot;, covering
           end-of-life topics such as symptom management, advanced care planning, communication
           with the health care team and family members, spirituality, and nutrition. Patients also
           receive information regarding the purpose and time/location of symptom management,
           shared medical appointments (SMAs), which they can attend in person or call in to
           participate via speaker phone. SMAs are 1.5-hour monthly sessions conducted by a
           physician and a nurse practitioner that can accommodate 10-12 patients and their
           caregivers. The sessions include a welcome/social period, a question and answer/peer
           discussion, an interactive educational session, and an opportunity for one-on-one nurse
           practitioner appointments with a focus on a brief review of the patients' medical
           treatment plans.

        -  Arm II (standard palliative care program): Patients receive standard palliative care
           from their physician/nurse practitioner team and have access to the palliative care
           nurse at the discretion of the treating physician.

      Patients complete Functional Assessment of Chronic Illness Therapy-Palliative Care at
      baseline and every 3 months thereafter. Patients and caregivers complete surveys measuring
      their perception of the quality of the patient's cancer care at baseline and at 1 month.

      A caregiver or family member completes the After-Death Bereaved Family Member Interview to
      evaluate the adequacy of patient care at 3 months post-patient death.

      PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life as measured by Functional Assessment of Cancer Therapy-Palliative care version (FACT-Pal) at baseline, one month, and every three months thereafter</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom management as measured by Edmunton Symptom Assessment Scale at baseline, one month, and every three months thereafter</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care utilization by a chart review of days in hospital, ICU, ER visits at baseline, one month, and every three months thereafter</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceased</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression as measured by Center for Epidemiological Studies-Depression (CES-D) at baseline, one month, and every three months thereafter</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Problem solving skills as measured by Social Problem-Solving Skills Inventory-revised at baseline and one month</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)</measure>
    <time_frame>Baseline, one month, every three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>ENABLE (concurrent palliative care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telephone based ENABLE educational intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supportive and palliative usual care services at DHMC, Behavioral</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>counseling intervention</intervention_name>
    <arm_group_label>ENABLE (concurrent palliative care)</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>educational intervention</intervention_name>
    <arm_group_label>ENABLE (concurrent palliative care)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
    <arm_group_label>ENABLE (concurrent palliative care)</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>ENABLE (concurrent palliative care)</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following advanced cancers:

               -  Stage IIIB or IV non-small cell lung cancer

               -  Extensive stage small cell lung cancer

               -  Stage IV breast cancer

                    -  Poor prognostic indicators (conferring likelihood of â‰¤ 2 years survival),
                       including, but not limited to, any of the following:

                         -  Visceral crisis

                         -  Lung or liver metastasis

                         -  Estrogen receptor-negative disease

                         -  HER2/neu-positive disease

                         -  Progressive or recurrent disease during or within 2 years of first
                            treatment

               -  Unresectable stage III or stage IV gastrointestinal cancers

               -  Stage IV genitourinary cancers

                    -  Prostate cancer must be hormone refractory

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Sex

          -  Not specified

        Menopausal status

          -  Not specified

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  No dementia or significant confusion (i.e., Mini Mental Exam score &lt; 25)

          -  No Axis I psychiatric disorders (DSM-IV), including any of the following:

               -  Schizophrenia

               -  Bipolar disorder

               -  Active substance use disorder

        PRIOR CONCURRENT THERAPY:

        Endocrine therapy

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie A Bakitas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - White River Junction</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009 Aug 19;302(7):741-9. doi: 10.1001/jama.2009.1198.</citation>
    <PMID>19690306</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional care planning</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>clear cell sarcoma of the kidney</keyword>
  <keyword>peripheral primitive neuroectodermal tumor of the kidney</keyword>
  <keyword>rhabdoid tumor of the kidney</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <keyword>stage IV penile cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

